Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 170Observational 5Expanded_access 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Polycythemia Vera 2Primary Myelofibrosis 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × ruxolitinib × Clear all
NCT04745637 2025-11-18

Managed Access Programs for INC424, Ruxolitinib

Novartis

Available
Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT05269771 2025-11-05

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Novartis

No longer available
Myeloid

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡